Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Ozanimod | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Ozanimod | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Ozanimod | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Ozanimod | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Ozanimod | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | Ozanimod | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Ozanimod | hsa00983 | Drug metabolism - other enzymes | 2.99E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Ozanimod | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Ozanimod | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Ozanimod | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Ozanimod | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | | Ozanimod | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Ozanimod | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Ozanimod | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Ozanimod | hsa04012 | ErbB signaling pathway | 1.91E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Ozanimod | hsa04060 | Cytokine-cytokine receptor interaction | 2.61E-02 | 10 | P27930, P08476, P25024, P25025, Q9UBD3, P47992, P01375, P09341, P18510, Q93038 | IL1R2, INHBA, CXCR1, CXCR2, XCL2, XCL1, TNF, CXCL1, IL1RN, TNFRSF25 | More | | Ozanimod | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.87E-02 | 6 | P09341, P25024, P25025, P47992, Q9UBD3, P01375 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, TNF | More | | Ozanimod | hsa04064 | NF-kappa B signaling pathway | 2.99E-02 | 7 | O00463, P14778, Q13077, Q16548, Q8WV28, P24522, P09341 | TRAF5, IL1R1, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | Ozanimod | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Ozanimod | hsa04080 | Neuroactive ligand-receptor interaction | 3.18E-05 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, ADRB2 | More | | Ozanimod | hsa04110 | Cell cycle | 8.83E-05 | 8 | Q9UBD5, P06493, O60566, Q14683, P30304, P33981, P42773, P01106 | ORC3, CDK1, BUB1B, SMC1A, CDC25A, TTK, CDKN2C, MYC | More | | Ozanimod | hsa04140 | Autophagy - animal | 4.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | Ozanimod | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Ozanimod | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Ozanimod | hsa04340 | Hedgehog signaling pathway | 9.74E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Ozanimod | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Ozanimod | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | | Ozanimod | hsa04612 | Antigen processing and presentation | 1.15E-05 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Ozanimod | hsa04613 | Neutrophil extracellular trap formation | 3.50E-06 | 22 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, Q93077, P58876, Q16778, O60814, P68431, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Ozanimod | hsa04625 | C-type lectin receptor signaling pathway | 5.58E-03 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | Ozanimod | hsa04640 | Hematopoietic cell lineage | 5.36E-03 | 12 | P13612, P14778, P27930, P15144, P11836, P09693, P01732, P01730, P06127, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF | More | | Ozanimod | hsa04650 | Natural killer cell mediated cytotoxicity | 1.76E-06 | 10 | P01375, P78314, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P01375 | TNF | Tumor necrosis factor | -0.856 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.812 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.85 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.824 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.766 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.8 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | Q9H228 | EDG8 | Sphingosine 1-phosphate receptor 5 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.8 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Ozanimod | hsa04657 | IL-17 signaling pathway | 1.75E-05 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Ozanimod | hsa04658 | Th1 and Th2 cell differentiation | 7.47E-03 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | | Ozanimod | hsa04659 | Th17 cell differentiation | 3.13E-02 | 8 | Q04759, Q16539, P13765, P14778, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, HLA-DOB, IL1R1, TBX21, GATA3, CD3G, CD247 | More | | Ozanimod | hsa04660 | T cell receptor signaling pathway | 8.00E-03 | 10 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Ozanimod | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | | Ozanimod | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | | Ozanimod | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Ozanimod | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | Ozanimod | hsa04912 | GnRH signaling pathway | 4.72E-02 | 4 | Q16539, Q9Y6R4, Q14643, P22694 | MAPK14, MAP3K4, ITPR1, PRKACB | More | | Ozanimod | hsa04913 | Ovarian steroidogenesis | 1.27E-03 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Ozanimod | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | Ozanimod | hsa04924 | Renin secretion | 2.90E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Ozanimod | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Ozanimod | hsa04927 | Cortisol synthesis and secretion | 1.27E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Ozanimod | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.02E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Ozanimod | hsa04932 | Non-alcoholic fatty liver disease | 3.62E-02 | 3 | P49841, Q16718, O14521 | GSK3B, NDUFA5, SDHD | More | | Ozanimod | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | | Ozanimod | hsa04970 | Salivary secretion | 9.44E-04 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | | Ozanimod | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Ozanimod | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Ozanimod | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Ozanimod | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Ozanimod | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | Ozanimod | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.59E-04 | 6 | Q16539, Q99437, P09341, P25024, P25025, P41240 | MAPK14, ATP6V0B, CXCL1, CXCR1, CXCR2, CSK | More | | Ozanimod | hsa05140 | Leishmaniasis | 1.01E-03 | 8 | P13612, O75015, P13765, O60603, P01375, P49006, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MARCKSL1, MAPK14, NCF4 | More | | Ozanimod | hsa05144 | Malaria | 9.55E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Ozanimod | hsa05146 | Amoebiasis | 4.45E-06 | 10 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | Ozanimod | hsa05150 | Staphylococcus aureus infection | 1.67E-02 | 5 | P21730, P21462, O75015, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA4, CAMP | More | | Ozanimod | hsa05163 | Human cytomegalovirus infection | 3.04E-03 | 8 | P01375, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Ozanimod | hsa05202 | Transcriptional misregulation in cancer | 3.62E-05 | 17 | P41732, P14780, P27930, Q15744, Q16548, P11215, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Ozanimod | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | Ozanimod | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Ozanimod | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Ozanimod | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Ozanimod | hsa05231 | Choline metabolism in cancer | 2.60E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Ozanimod | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | | Ozanimod | hsa05321 | Inflammatory bowel disease | 7.75E-06 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Ozanimod | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | | Ozanimod | hsa05332 | Graft-versus-host disease | 1.03E-04 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | Ozanimod | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Ozanimod | hsa05418 | Fluid shear stress and atherosclerosis | 1.26E-04 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |